Diffusion MRI is an early biomarker of overall survival benefit in IDH wild-type recurrent glioblastoma treated with immune checkpoint inhibitors.
Hagiwara A, Oughourlian TC, Cho NS, Schlossman J, Wang C, Yao J, Raymond C, Everson R, Patel K, Mareninov S, Rodriguez FJ, Salamon N, Pope WB, Nghiemphu PL, Liau LM, Prins RM, Cloughesy TF, Ellingson BM.
Hagiwara A, et al. Among authors: ellingson bm.
Neuro Oncol. 2022 Jun 1;24(6):1020-1028. doi: 10.1093/neuonc/noab276.
Neuro Oncol. 2022.
PMID: 34865129
Free PMC article.